Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers

Trial Details

NCT ID
NCT06563388
Phase
PHASE3
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Stereotactic Ablative Radiotherapy
  • Best Practice
Locations (sample)
  • Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

  • Age 1 year or older.
  • Willing to provide informed consent.
  • Life expectancy \> 6 months.
  • Trials 1-3: Histologically confirmed lung, prostate or colorectal malignancy with metastatic disease detected on imaging. Biopsy of metastasis is p…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →